• Consensus Rating: Buy
  • Consensus Price Target: $440.92
  • Forecasted Upside: 9.60 %
  • Number of Analysts: 14
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 11 Buy Ratings
  • 1 Strong Buy Ratings
▲ +3.09 (0.77%)

This chart shows the closing price for ARGX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New argenx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARGX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARGX

Analyst Price Target is $440.92
▲ +9.60% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for argenx in the last 3 months. The average price target is $440.92, with a high forecast of $480.00 and a low forecast of $340.00. The average price target represents a 9.60% upside from the last price of $402.31.

This chart shows the closing price for ARGX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 14 contributing investment analysts is to buy stock in argenx. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 14 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 15 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 15 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 15 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 16 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 15 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 1 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/14/2022JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight€470.00 ➝ €480.00Low
10/28/2022Morgan StanleyBoost TargetOverweight$401.00 ➝ $450.00Low
10/28/2022Truist FinancialBoost TargetBuy$410.00 ➝ $420.00Low
10/28/2022HC WainwrightBoost TargetBuy$425.00 ➝ $440.00Low
10/28/2022SVB LeerinkBoost TargetOutperform$428.00 ➝ $430.00Low
10/21/2022Evercore ISIUpgradeOutperformLow
10/18/2022Wells Fargo & CompanyBoost TargetOverweight$461.00 ➝ $469.00Low
10/11/2022OppenheimerInitiated CoverageMarket PerformLow
9/22/2022Deutsche Bank AktiengesellschaftBoost TargetBuy ➝ Buy€400.00 ➝ €425.00Low
9/22/2022JMP SecuritiesReiterated RatingBuy$427.00Low
8/26/2022Piper SandlerBoost TargetOverweight$450.00 ➝ $465.00Low
7/29/2022HC WainwrightBoost TargetBuy$400.00 ➝ $425.00Low
7/29/2022SVB LeerinkBoost TargetOutperform$404.00 ➝ $428.00Low
7/29/2022Robert W. BairdReiterated RatingDowngradeLow
7/29/2022Morgan StanleyBoost TargetOverweight$375.00 ➝ $401.00Low
7/28/2022Robert W. BairdDowngradeOutperform ➝ Neutral$374.00 ➝ $460.00Low
7/28/2022Stifel NicolausBoost Target$460.00 ➝ $471.00Low
7/25/2022Piper SandlerBoost TargetOverweight$415.00 ➝ $425.00Low
7/14/2022JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight€390.00 ➝ €430.00Low
6/27/2022Stifel NicolausInitiated CoverageBuy$460.00Low
5/27/2022Piper SandlerBoost TargetOverweight$375.00 ➝ $415.00Medium
5/24/2022SVB LeerinkReiterated RatingOutperformLow
5/13/2022Deutsche Bank AktiengesellschaftUpgradeHold ➝ BuyMedium
5/6/2022JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight€350.00 ➝ €370.00Low
5/3/2022Morgan StanleyUpgradeEqual Weight ➝ Overweight$375.00Low
3/7/2022Morgan StanleyBoost TargetEqual Weight$274.00 ➝ $278.00Medium
3/4/2022HC WainwrightReiterated RatingBuy$400.00Medium
2/1/2022Morgan StanleyLower TargetEqual Weight$339.00 ➝ $274.00High
1/18/2022Morgan StanleyLower TargetEqual Weight$351.00 ➝ $339.00Medium
1/4/2022JPMorgan Chase & Co.Boost Target€340.00 ➝ €350.00High
12/21/2021Truist FinancialBoost TargetBuy ➝ Buy$350.00 ➝ $365.00Medium
12/21/2021JMP SecuritiesBoost TargetMarket Outperform$368.00 ➝ $418.00Low
12/20/2021Wells Fargo & CompanyBoost TargetOverweight$390.00 ➝ $395.00Medium
12/20/2021Credit Suisse GroupBoost TargetNeutral$297.00 ➝ $340.00Medium
12/20/2021Raymond JamesBoost TargetStrong-Buy$390.00 ➝ $455.00Medium
12/8/2021Wells Fargo & CompanyInitiated CoverageOverweight$390.00High
12/2/2021Kepler Capital MarketsUpgradeHold ➝ Buy$220.00 ➝ $290.00Medium
11/29/2021Piper SandlerUpgradeNeutral ➝ Overweight$250.00 ➝ $354.00High
10/28/2021GuggenheimUpgradeNeutral ➝ Buy$330.00High
10/28/2021Raymond JamesUpgradeOutperform ➝ Strong-Buy$390.00Low
10/19/2021BarclaysUpgradeEqual Weight ➝ OverweightLow
10/6/2021Jefferies Financial GroupInitiated CoverageBuy$362.00High
10/4/2021Robert W. BairdBoost TargetOutperform$333.00 ➝ $355.00Low
9/23/2021Redburn PartnersUpgradeNeutral ➝ Buy$205.00 ➝ $325.00Low
9/7/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$332.00 ➝ $351.00Medium
9/2/2021BarclaysReiterated RatingEqual WeightLow
8/4/2021JPMorgan Chase & Co.Reiterated RatingOverweightLow
8/3/2021Morgan StanleyBoost TargetOverweight$324.00 ➝ $332.00Low
7/23/2021Deutsche Bank AktiengesellschaftInitiated CoverageHold$250.00Low
7/22/2021WedbushBoost TargetOutperform$344.00 ➝ $362.00Medium
7/21/2021HC WainwrightReiterated RatingBuy$400.00Low
6/18/2021UBS GroupInitiated CoverageBuy$390.00Medium
6/8/2021WedbushLower TargetPositive ➝ Outperform$356.00 ➝ $344.00Low
6/7/2021Piper SandlerLower TargetNeutral$309.00 ➝ $250.00High
5/18/2021Morgan StanleyBoost TargetOverweight$321.00 ➝ $324.00Medium
5/16/2021Kepler Capital MarketsDowngradeHoldHigh
5/10/2021HC WainwrightUpgradeNeutral ➝ Buy$320.00 ➝ $400.00Medium
4/23/2021Redburn PartnersInitiated CoverageNeutralLow
4/19/2021Morgan StanleyLower TargetOverweight$326.00 ➝ $321.00Low
3/8/2021Morgan StanleyBoost TargetOverweight$311.00 ➝ $326.00Low
3/5/2021Kepler Capital MarketsReiterated RatingHoldMedium
3/5/2021HC WainwrightBoost TargetNeutral$265.00 ➝ $320.00Medium
2/18/2021CowenBoost TargetOutperform$317.00 ➝ $430.00Low
2/10/2021BarclaysReiterated RatingEqual WeightLow
2/4/2021Piper SandlerBoost Target$303.00 ➝ $309.00Low
2/2/2021Wells Fargo & CompanyBoost TargetEqual Weight$272.00 ➝ $326.00Low
2/1/2021Piper SandlerDowngradeOverweight ➝ Neutral$300.00 ➝ $303.00Low
2/1/2021JMP SecuritiesReiterated RatingPositive ➝ Outperform$307.00 ➝ $421.00Low
1/7/2021Wells Fargo & CompanyBoost TargetEqual Weight$249.00 ➝ $272.00N/A
1/7/2021JMP SecuritiesBoost TargetOutperform$271.00 ➝ $307.00N/A
1/4/2021GuggenheimDowngradeBuy ➝ NeutralN/A
12/16/2020Morgan StanleyBoost TargetOverweight$295.00 ➝ $311.00Medium
12/15/2020Truist FinancialBoost Target$275.00 ➝ $350.00Low
11/11/2020Morgan StanleyBoost TargetOverweight$281.00 ➝ $295.00Low
10/29/2020JPMorgan Chase & Co.Reiterated RatingOverweightLow
10/23/2020BarclaysReiterated RatingEqual WeightLow
10/23/2020HC WainwrightLower TargetNeutral$272.00 ➝ $265.00Medium
10/13/2020BarclaysReiterated RatingEqual WeightMedium
10/6/2020Bank of AmericaBoost TargetBuy$265.00 ➝ $298.00Low
10/6/2020Robert W. BairdBoost TargetPositive ➝ Outperform$265.00 ➝ $275.00Low
10/5/2020JMP SecuritiesBoost TargetOutperform$245.00 ➝ $271.00High
9/30/2020Piper SandlerBoost TargetPositive ➝ Overweight$258.00 ➝ $300.00Low
8/24/2020Raymond JamesInitiated CoverageOutperform$257.00Medium
8/10/2020Morgan StanleyBoost TargetOverweight$258.00 ➝ $281.00Medium
7/31/2020Kepler Capital MarketsDowngradeBuy ➝ HoldLow
7/30/2020Stifel NicolausReiterated RatingBuy$253.00Medium
7/29/2020HC WainwrightInitiated CoverageNeutral$272.00High
6/17/2020CowenReiterated RatingBuyLow
5/29/2020JPMorgan Chase & Co.Boost TargetOverweight$179.00 ➝ $246.00Medium
5/27/2020Morgan StanleyBoost TargetOverweight$180.00 ➝ $258.00Low
5/27/2020GuggenheimReiterated RatingBuy$201.00 ➝ $225.00Medium
5/27/2020Robert W. BairdBoost TargetPositive ➝ Outperform$170.00 ➝ $235.00Medium
5/27/2020SunTrust BanksBoost TargetBuy$192.00 ➝ $240.00Medium
5/26/2020JMP SecuritiesBoost TargetOutperform$170.00 ➝ $237.00High
5/26/2020Piper SandlerBoost Target$198.00 ➝ $258.00High
5/26/2020Stifel NicolausBoost TargetPositive ➝ Buy$163.00 ➝ $253.00High
5/21/2020Credit Suisse GroupBoost TargetNeutral$150.00 ➝ $160.00Medium
5/17/2020NomuraReiterated RatingBuy$255.00High
5/14/2020Stifel NicolausReiterated RatingBuy$163.00High
3/4/2020Nomura SecuritiesReiterated RatingBuy$255.00High
2/24/2020GuggenheimBoost TargetBuy$164.00 ➝ $201.00Low
2/10/2020Bank of AmericaInitiated CoverageBuy$181.00Low
1/17/2020WedbushReiterated RatingOutperform$184.00 ➝ $184.00Low
1/17/2020Morgan StanleyBoost TargetOverweight$170.00 ➝ $180.00Medium
1/9/2020WedbushBoost TargetPositive ➝ Outperform$179.00 ➝ $184.00Medium
1/9/2020JMP SecuritiesReiterated RatingOutperform$164.00 ➝ $170.00Medium
1/9/2020Stifel NicolausReiterated RatingBuy ➝ AverageHigh
1/6/2020Piper Jaffray CompaniesBoost TargetOverweight$177.00 ➝ $194.00N/A
12/16/2019SunTrust BanksBoost TargetBuy$160.00 ➝ $192.00Medium
12/8/2019Stifel NicolausBoost TargetBuy$154.00 ➝ $170.00High
11/18/2019SunTrust BanksBoost TargetBuy$150.00 ➝ $160.00Low
11/8/2019Piper Jaffray CompaniesReiterated RatingOverweightLow
11/5/2019Credit Suisse GroupInitiated CoverageNeutral$137.00 ➝ $137.00Low
10/31/2019William BlairUpgradeMarket Perform ➝ OutperformLow
10/22/2019JPMorgan Chase & Co.Initiated CoverageOverweight$167.00Low
9/27/2019Wells Fargo & CompanyInitiated CoverageMarket Perform$125.00Medium
9/13/2019CowenInitiated CoverageBuyMedium
8/6/2019Morgan StanleyBoost TargetOverweight$143.00 ➝ $173.00Medium
8/2/2019WedbushBoost TargetOutperform$144.00 ➝ $170.00Low
8/1/2019Stifel NicolausReiterated RatingBuy$154.00Low
6/27/2019Robert W. BairdInitiated CoverageOutperform ➝ Outperform$170.00High
5/23/2019Piper Jaffray CompaniesBoost TargetOverweight$161.00 ➝ $182.00High
5/22/2019Stifel NicolausSet TargetBuy$154.00High
3/1/2019WedbushBoost TargetOutperform ➝ Outperform$131.00 ➝ $144.00Medium
2/22/2019GuggenheimInitiated CoverageBuy$157.00High
2/4/2019Stifel NicolausReiterated RatingBuyLow
1/18/2019SunTrust BanksReiterated RatingBuy ➝ BuyLow
1/4/2019Morgan StanleyInitiated CoverageOverweight ➝ Overweight$140.00Low
12/17/2018The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$154.00Low
12/14/2018Wolfe ResearchInitiated CoverageOutperform ➝ OutperformLow
12/9/2018CowenReiterated RatingBuyLow
12/4/2018Piper Jaffray CompaniesBoost TargetOverweight$154.00 ➝ $161.00Low
12/4/2018WedbushBoost TargetOutperform ➝ Outperform$130.00 ➝ $131.00Medium
11/5/2018WedbushReiterated RatingOutperform ➝ Outperform$130.00 ➝ $125.00Medium
11/1/2018Stifel NicolausReiterated RatingBuyHigh
10/25/2018Stifel NicolausSet TargetBuy$139.00Low
10/16/2018Stifel NicolausSet TargetBuy$139.00High
10/15/2018Evercore ISIInitiated CoverageOutperform$110.00Medium
10/10/2018Stifel NicolausReiterated RatingBuy$139.00High
9/18/2018SunTrust BanksBoost TargetBuy ➝ In-Line$132.00High
9/18/2018WedbushBoost TargetOutperform ➝ Positive$114.00 ➝ $121.00High
9/17/2018JMP SecuritiesBoost TargetOutperform$150.00High
9/17/2018Piper Jaffray CompaniesReiterated RatingPositive ➝ Overweight$154.00High
9/13/2018Stifel NicolausInitiated CoverageBuy$139.00High
6/29/2018Nomura SecuritiesInitiated CoverageBuy$161.00High
6/25/2018WedbushBoost TargetOutperform ➝ Outperform$93.00 ➝ $114.00High
6/18/2018JMP SecuritiesBoost TargetPositive$93.00 ➝ $130.00Low
6/14/2018CowenReiterated RatingBuyLow
6/7/2018Piper Jaffray CompaniesReiterated RatingOverweight$130.00Medium
6/6/2018CowenReiterated RatingBuyHigh
5/10/2018WedbushReiterated RatingOutperform$93.00 ➝ $92.00Low
4/26/2018WedbushBoost TargetOutperform ➝ Outperform$88.00 ➝ $92.00Low
4/8/2018SunTrust BanksInitiated CoverageBuy ➝ Buy$125.00High
1/29/2018JMP SecuritiesBoost TargetMkt Outperform ➝ Outperform$74.00 ➝ $87.00High
12/19/2017Piper Jaffray CompaniesBoost TargetOverweight$100.00Low
(Data available from 12/5/2017 forward)

News Sentiment Rating

0.97 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
  • 3 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 4 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
  • 5 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 7 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 5 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 5 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
argenx logo
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Read More

Today's Range

Now: $402.31
Low: $396.00
High: $405.00

50 Day Range

MA: $368.52
Low: $343.75
High: $402.31

52 Week Range

Now: $402.31
Low: $249.50
High: $407.93


164,400 shs

Average Volume

269,867 shs

Market Capitalization

$22.26 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of argenx?

The following equities research analysts have issued stock ratings on argenx in the last twelve months: Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Evercore ISI, HC Wainwright, JMP Securities, JPMorgan Chase & Co., Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Robert W. Baird, Stifel Nicolaus, SVB Leerink LLC, Truist Financial Co., and Wells Fargo & Company.
View the latest analyst ratings for ARGX.

What is the current price target for argenx?

13 Wall Street analysts have set twelve-month price targets for argenx in the last year. Their average twelve-month price target is $440.92, suggesting a possible upside of 9.6%. JPMorgan Chase & Co. has the highest price target set, predicting ARGX will reach $480.00 in the next twelve months. Credit Suisse Group AG has the lowest price target set, forecasting a price of $340.00 for argenx in the next year.
View the latest price targets for ARGX.

What is the current consensus analyst rating for argenx?

argenx currently has 2 hold ratings, 11 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ARGX will outperform the market and that investors should add to their positions of argenx.
View the latest ratings for ARGX.

What other companies compete with argenx?

How do I contact argenx's investor relations team?

argenx's physical mailing address is Willemstraat 5, Breda P7, 4811 AH. The company's listed phone number is (176) 303-0488 and its investor relations email address is [email protected] The official website for argenx is www.argenx.com. Learn More about contacing argenx investor relations.